Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

United Therapeutics Corp (NASDAQ:UTHR)

149.22
Delayed Data
As of 11:37am ET
 +1.28 / +0.87%
Today’s Change
97.52
Today|||52-Week Range
153.07
+4.04%
Year-to-Date
CT Financial Advisors LLC Buys Alphabet Inc, Alphabet Inc, United Therapeutics Corp, ...
Jan 12 / GuruFocus News - Paid Partner Content
New Strong Buy Stocks for January 5th
Jan 05 / Zacks.com - Paid Partner Content
VIVUS Licenses Rights to PAH Drugs from Selten Pharma
Jan 11 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close147.94
Today’s open149.13
Day’s range147.98 - 150.35
Volume170,679
Average volume (3 months)592,788
Market cap$6.3B
Dividend yield--
Data as of 11:37am ET, 01/18/2017

Growth & Valuation

Earnings growth (last year)+102.55%
Earnings growth (this year)+28.84%
Earnings growth (next 5 years)+16.65%
Revenue growth (last year)+13.76%
P/E ratio10.0
Price/Sales5.47
Price/Book4.26

Competitors

 Today’s
change
Today’s
% change
IONSIonis Pharmaceutical...-0.13-0.28%
JAZZJazz Pharmaceuticals...+11.93+10.32%
MNKMallinckrodt Plc-0.04-0.08%
VRXValeant Pharmaceutic...-0.15-0.98%
Data as of 11:52am ET, 01/18/2017

Financials

Next reporting dateFebruary 28, 2017
EPS forecast (this quarter)$3.76
Annual revenue (last year)$1.5B
Annual profit (last year)$651.6M
Net profit margin44.46%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
Martine A. Rothblatt
President &
Chief Operating Officer
Michael Benkowitz
Corporate headquarters
Silver Spring, Maryland

Forecasts


Search for Jobs